JP2016138129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016138129A5 JP2016138129A5 JP2016078639A JP2016078639A JP2016138129A5 JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5 JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fcγriib
- composition
- target cell
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 33
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 31
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 31
- 238000000034 method Methods 0.000 claims 29
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 101710160107 Outer membrane protein A Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 1
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1013989.7A GB201013989D0 (en) | 2010-08-20 | 2010-08-20 | Biological materials and methods of using the same |
| GB1013989.7 | 2010-08-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Division JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016138129A JP2016138129A (ja) | 2016-08-04 |
| JP2016138129A5 true JP2016138129A5 (cg-RX-API-DMAC7.html) | 2017-06-08 |
| JP6421140B2 JP6421140B2 (ja) | 2018-11-07 |
Family
ID=42984443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
| JP2016078639A Active JP6421140B2 (ja) | 2010-08-20 | 2016-04-11 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10525129B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2606068B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6215704B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101948609B1 (cg-RX-API-DMAC7.html) |
| CN (7) | CN114099668B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011290503B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2808744C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2606068T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2653685T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201013989D0 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE037478T2 (cg-RX-API-DMAC7.html) |
| NO (1) | NO2606068T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2606068T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2606068T (cg-RX-API-DMAC7.html) |
| RU (2) | RU2769949C2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2606068T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012022985A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| CA2892750A1 (en) * | 2012-11-29 | 2014-06-05 | Bayer Healthcare Llc | Monoclonal antibodies agaisnt activated protein c (apc) |
| ES2730690T3 (es) * | 2012-12-07 | 2019-11-12 | Suppremol Gmbh | Estratificación y tratamiento de pacientes que padecen púrpura trombocitopénica idiopática |
| CA2902432A1 (en) | 2013-03-12 | 2014-10-09 | Molecular Templates, Inc. | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| ES2877356T3 (es) | 2014-01-27 | 2021-11-16 | Molecular Templates Inc | Epítopo de MHC de clase I que suministra polipéptidos |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| GB2526139A (en) * | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| AU2015274647C1 (en) | 2014-06-11 | 2020-01-30 | Molecular Templates, Inc. | Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same |
| MX2017010072A (es) | 2015-02-05 | 2017-11-09 | Molecular Templates Inc | Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas. |
| RU2733496C2 (ru) * | 2015-03-16 | 2020-10-02 | Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) | Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний |
| MX2017015493A (es) | 2015-05-30 | 2018-02-09 | Molecular Templates Inc | Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden. |
| JP2019506844A (ja) | 2015-12-18 | 2019-03-14 | ノバルティス アーゲー | ＣＤ３２ｂを標的とする抗体およびその使用方法 |
| CN110087530A (zh) | 2016-12-07 | 2019-08-02 | 普罗根尼蒂公司 | 胃肠道检测方法、装置和系统 |
| WO2018106895A1 (en) | 2016-12-07 | 2018-06-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
| JP7082424B2 (ja) | 2017-01-25 | 2022-06-08 | モレキュラー テンプレーツ，インク． | 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子 |
| EP3573640A4 (en) * | 2017-01-30 | 2021-04-28 | The Ohio State Innovation Foundation | PASSIVE ANTIBODY DEPENDENT CELLULAR MEDIATION ACTIVATION |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| WO2019204272A1 (en) | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
| CN108823211A (zh) * | 2018-05-04 | 2018-11-16 | 中国医学科学院基础医学研究所 | 一种cd19核酸适配体及其应用 |
| BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| JP2022541249A (ja) * | 2019-07-17 | 2022-09-22 | バイオインベント インターナショナル アクティエボラーグ | 特定の患者のがんを治療するための抗体の組み合わせ |
| WO2021076196A1 (en) * | 2019-10-18 | 2021-04-22 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| KR20230038180A (ko) * | 2020-06-04 | 2023-03-17 | 바이오인벤트 인터내셔날 에이비 | 정맥 내 투여와 관련된 항체 관용성 개선 |
| EP3919077A1 (en) | 2020-06-04 | 2021-12-08 | BioInvent International AB | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| TW202336033A (zh) | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| TW202346359A (zh) | 2022-04-15 | 2023-12-01 | 美商凱維那醫療公司 | 用於治療自體免疫疾病之方法及組合物 |
| WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| AU666852B2 (en) | 1991-05-01 | 1996-02-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| JP2000506165A (ja) | 1996-03-04 | 2000-05-23 | ザ ペン ステイト リサーチ ファウンデーション | 細胞インターナリゼーションを増強するための物質および方法 |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| PT954282E (pt) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | Preparacao de particulas para inalacao |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| RU2305561C2 (ru) * | 1999-11-08 | 2007-09-10 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией |
| ATE536188T1 (de) * | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| WO2005018669A1 (en) * | 2003-08-18 | 2005-03-03 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| EP1709073B1 (en) | 2003-11-26 | 2011-08-10 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb) |
| WO2005115452A2 (en) * | 2004-04-16 | 2005-12-08 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| JP2007536932A (ja) * | 2004-05-10 | 2007-12-20 | マクロジェニクス，インコーポレーテッド | ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| WO2006048781A2 (en) * | 2004-05-20 | 2006-05-11 | St. Mary's Hospital Nhs Trust | IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| EP1833849A4 (en) * | 2004-12-15 | 2009-08-05 | Macrogenics Inc | FC-GAMMA-RIIB-SPECIFIC ANTIBODIES AND METHODS FOR THEIR USE |
| EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
| EP2032159B1 (en) * | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| WO2009062051A2 (en) * | 2007-11-08 | 2009-05-14 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| WO2009083009A2 (en) * | 2008-01-03 | 2009-07-09 | Genmab A/S | Monoclonal antibodies against cd32b |
| WO2010080994A2 (en) | 2009-01-08 | 2010-07-15 | The Uab Research Foundation | Process for regulating immune response |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
-
2010
- 2010-08-20 GB GBGB1013989.7A patent/GB201013989D0/en not_active Ceased
-
2011
- 2011-08-19 PT PT117608190T patent/PT2606068T/pt unknown
- 2011-08-19 ES ES11760819.0T patent/ES2653685T3/es active Active
- 2011-08-19 DK DK11760819.0T patent/DK2606068T3/da active
- 2011-08-19 CA CA2808744A patent/CA2808744C/en active Active
- 2011-08-19 KR KR1020137006990A patent/KR101948609B1/ko active Active
- 2011-08-19 RU RU2017143633A patent/RU2769949C2/ru active
- 2011-08-19 US US13/817,744 patent/US10525129B2/en active Active
- 2011-08-19 RU RU2013112345/10A patent/RU2013112345A/ru unknown
- 2011-08-19 HU HUE11760819A patent/HUE037478T2/hu unknown
- 2011-08-19 AU AU2011290503A patent/AU2011290503B2/en active Active
- 2011-08-19 CN CN202110959354.9A patent/CN114099668B/zh active Active
- 2011-08-19 CN CN201710789909.3A patent/CN107670034B/zh active Active
- 2011-08-19 EP EP11760819.0A patent/EP2606068B1/en active Active
- 2011-08-19 EP EP17184259.4A patent/EP3263602A1/en not_active Withdrawn
- 2011-08-19 CN CN202110959352.XA patent/CN114099666B/zh active Active
- 2011-08-19 CN CN202110959481.9A patent/CN114099669A/zh active Pending
- 2011-08-19 JP JP2013524483A patent/JP6215704B2/ja active Active
- 2011-08-19 CN CN201180040351XA patent/CN103080131A/zh active Pending
- 2011-08-19 SI SI201131366T patent/SI2606068T1/en unknown
- 2011-08-19 PL PL11760819T patent/PL2606068T3/pl unknown
- 2011-08-19 CN CN202110959355.3A patent/CN114099702B/zh active Active
- 2011-08-19 NO NO11760819A patent/NO2606068T3/no unknown
- 2011-08-19 WO PCT/GB2011/051572 patent/WO2012022985A1/en not_active Ceased
- 2011-08-19 CN CN202110959353.4A patent/CN114099667B/zh active Active
-
2016
- 2016-04-11 JP JP2016078639A patent/JP6421140B2/ja active Active
-
2019
- 2019-11-14 US US16/684,450 patent/US11623005B2/en active Active
-
2021
- 2021-06-25 US US17/359,496 patent/US20210346498A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/177,050 patent/US20230381310A1/en active Pending